可诱导性缺血作为稳定性冠心病不良结局替代指标的效度
本文讨论稳定性冠心病中可诱导性心肌缺血作为不良临床结局替代指标的效度。队列研究中缺血检测未能影响心肌梗死和冠心病死亡发生率,而有效纠正缺血的药物和介入治疗很少显示降低心血管风险。以症状驱动的管理策略可能减少不必要的负荷试验和血运重建。
要点
- 缺血检测未显著影响稳定性冠心病患者心肌梗死和冠心病死亡发生率。
- 有效纠正缺血的药物和介入治疗很少显示降低心血管风险。
- 症状驱动管理策略可能减少不必要的负荷试验和血运重建。
核心结论
- 可诱导性心肌缺血作为稳定性冠心病不良临床结局替代指标的效度尚未充分确立。
研究设计与样本
- 本文为针对稳定性冠心病中缺血作为替代指标效度的论述性文章,未报告系统检索范围。
主要发现
- 队列研究中缺血检测未能影响心肌梗死和冠心病死亡发生率。
- 临床研究中有效纠正缺血的药物和介入治疗很少显示降低心血管风险。
- 他汀和其他抗炎药物对缺血无直接影响但通过改变动脉粥样硬化血栓形成过程改善心血管结局。
临床怎么用
- 稳定性冠心病随访中不应将缺血变化本身作为治疗目标而独立于症状状态。
- 以症状驱动的管理策略可能减少非侵入性负荷试验、不必要的下游血运重建和宝贵资源使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Regional myocardial ischaemia is commonly expressed as exertional angina in patients with stable coronary artery disease (CAD). It also associates with prognosis, risk tending to increase with the severity of ischaemia. The validity of myocardial ischaemia as a surrogate for adverse clinical outcomes, however, has not been well established. Thus, in cohort studies, ischaemia testing has failed to influence rates of myocardial infarction and coronary death. Moreover, in clinical studies, pharmacological and interventional treatments that are effective in correcting ischaemia have rarely been shown to reduce cardiovascular (CV) risk. This contrasts with statins and other anti-inflammatory drugs that have no direct effect on ischaemia but improve CV outcomes by modifying the atherothrombotic disease process. Despite this, and with little evidence of patient benefit, stress testing is commonly used during the follow-up of patients with stable CAD when the demonstration of ischaemic change may be seen as a target for treatment, independently of symptomatic status. Substitution of a symptom-driven management strategy has the potential to reduce rates of non-invasive stress testing, unnecessary downstream revascularisation procedures and use of valuable resources in patients with stable CAD without adverse consequences for CV risk.
引用
- Timmis A, Raharja A, Archbold RA, et al. Validity of inducible ischaemia as a surrogate for adverse outcomes in stable coronary artery disease. Heart. 2018. PMID: 29875140. doi:10.1136/heartjnl-2018-313230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。